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Abstract
Background: Confusion between similar drug names is a common cause of potentially harmful medication errors.
Interventions to prevent these errors at the point of prescribing have had limited success. The purpose of this study is to
measure whether indication alerts at the time of computerized physician order entry (CPOE) can intercept drug name
confusion errors.
Methods and Findings: A retrospective observational study of alerts provided to prescribers in a public, tertiary hospital
and ambulatory practice with medication orders placed using CPOE. Consecutive patients seen from April 2006 through
February 2012 were eligible if a clinician received an indication alert during ordering. A total of 54,499 unique patients were
included. The computerized decision support system prompted prescribers to enter indications when certain medications
were ordered without a coded indication in the electronic problem list. Alerts required prescribers either to ignore them by
clicking OK, to place a problem in the problem list, or to cancel the order. Main outcome was the proportion of indication
alerts resulting in the interception of drug name confusion errors. Error interception was determined using an algorithm to
identify instances in which an alert triggered, the initial medication order was not completed, and the same prescriber
ordered a similar-sounding medication on the same patient within 5 minutes. Similarity was defined using standard text
similarity measures. Two clinicians performed chart review of all cases to determine whether the first, non-completed
medication order had a documented or non-documented, plausible indication for use. If either reviewer found a plausible
indication, the case was not considered an error. We analyzed 127,458 alerts and identified 176 intercepted drug name
confusion errors, an interception rate of 0.146.01%.
Conclusions: Indication alerts intercepted 1.4 drug name confusion errors per 1000 alerts. Institutions with CPOE should
consider using indication prompts to intercept drug name confusion errors.
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Introduction
Confusions between drug names that look and sound alike are a
common, costly and persistent type of medication error (e.g.,
hydroxyzine/hydralazine, Fosamax/Flomax, Durasal/Durezol)
[1–3]. Wrong drug errors, of which drug name confusions are
thought to be the most common type, occur at the rate of at least
one per thousand prescriptions in the inpatient [4–6] and
outpatient settings [7]. Regulatory agencies and the pharmaceu-
tical industry have taken steps to reduce the risk of these errors,
[8,9] but few interventions have produced convincing evidence of
sustained improvement in wrong drug error rates, especially at the
point of prescribing. Barcoding has been shown to be useful in
preventing wrong drug errors, but at the time of administration
[6]. So-called ‘tall-man’ lettering, where capitalization is used to
make similar names more distinctive (e.g., hydrOXYzine/
hydrALAzine), has had mixed success in lab experiments, but
there is no published evidence of its real-world impact [10–12].
Developing additional effective methods to reduce the rate of drug
name confusion errors is an important medication safety priority.
As part of a separate project, we developed and implemented a
set of clinical decision support (CDS) alerts to prompt prescribers
to add problems to the electronic medical record (EMR) problem
list when the prescriber ordered selected medications in the
absence of a documented indication (e.g., prescribing metformin
when diabetes was not on the problem list). We have previously
shown that these indication alerts improve problem list documen-
tation, with an acceptable error rate. The performance of such
alerts varies across medications, and appears to be a function of
the number of legitimate indications that exist for a given
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with few indications perform well) [13–15].
We recently reported on the ability of indication alerts to
intercept wrong patient errors at a rate of roughly 1 per 4000
alerted orders [16]. The mechanism by which the alerts intercept
errors is not completely clear, but we typically find that the
appearance of an alert forces the prescriber to take a brief ‘‘time
out’’ in the medication order process. During this time, the
prescriber may reflect on the patient, medication and indication in
relation to one another, and this additional reflection potentially
allows errors to be self-identified and self-corrected. Indication
alerts may function in a similar way to intercept drug name
confusion errors. If a clinician were to inadvertently select an
incorrect medication due to a pick-list or memory error, she would
have an opportunity to recognize the mistake when forced by the
alert to interrupt the ordering process and review the selected
drug’s indication in the context of the current patient and the
indication being suggested by the alert. The aim of this study was
to quantify the extent to which indication-based alerts during
computerized physician order entry (CPOE) of medications could
help intercept imminent drug name confusion errors prior to
completion of the order.
Methods
Setting
The University of Illinois Hospital and Health Sciences System
(UI-Health) is comprised of a 450-bed tertiary care hospital, large
multi-specialty ambulatory care clinic, emergency department and
19 community clinics. All clinical areas utilize a commercial EMR
(Millennium, Cerner Corporation, Kansas City, MO) for problem
lists, clinical notes, test results, medication lists and orders. The
EMR allowed any clinician to update patient records and problem
lists either as free text or using common, discrete-coded
nomenclatures (ICD-9 CM or SNOMED). Almost all medication
orders are placed by CPOE, which is associated with a
commercially available CDS system (Discern Expert, Cerner
Corporation), described previously for indication alerts [12] and
other types of alerts [13,17,18].
Clinical Decision Support
In the CDS system we developed and implemented, orders for a
selected subset of medications (Table 1) triggered an alert for the
clinician to update the medical record if the patient’s electronic
problem list did not contain an active condition indicated by that
medication (e.g., prescribing metformin when diabetes is not on
the problem list) [13]. Depending on the medication, alerts
displayed one or more possible diagnoses (Figure 1). The clinician
could select one or more of the offered indications, ignore the
alert, or cancel the order. Once selected, indications were added
automatically to the patient’s problem list in the EMR. The
medications were selected to maximize accurate problem list
placement, due to their frequent use and relatively limited
indications.
Specific sets of alerts were designed for selected diagnostic
categories and implemented from April 2006 through July 2010.
Almost all alerts were active throughout the medical center:
inpatient, outpatient and the emergency department (ED). Certain
medications were only active in the outpatient setting since their
use in the inpatient setting was non-specific for a particular disease
(e.g., insulins).
Detecting Intercepted Errors
In order to identify potential drug name confusion errors, we
analyzed all indication alerts triggered from April 2006 through
February 2012 to identify instances of orders that may have been
cancelled due to physician recognition of the error. For an alert to
be confirmed by chart review as an actual error, all of the
following criteria had to be met, with steps (a), (b), and (c) done by
computer program
(a) An order was started but not completed for a given
medication.
(b) The same prescriber completed an order for another
medication on the same patient within 5 minutes of the
initial order.
(c) The canceled medication name and subsequent completed
medication order name had a Bisim [19] and Editex [20]
similarity score greater than or equal to 0.40. The value 0.40
was chosen somewhat arbitrarily, based on examination of
the distribution of similarity scores for a large set of name
pairs known to be confusing. Bisim and Editex are
orthographic, ‘‘look alike’’ and phonetic, ‘‘sound alike’’,
measures [18–19].
(d) Two experienced clinicians, blinded to each other’s review,
determined that the medication whose order was cancelled
did not have a plausible indication for use, either through
documentation in the problem list or by review of clinical
documentation.
If either reviewer determined that the chart documented a
legitimate indication for the initial medication order, the case was
not counted as an intercepted error. This approach is more
conservative than using a third reviewer, since any disagreement
was sufficient to disqualify a case as an error. The presence of a
chronic indication was not always a reason to rule a case out as an
intercepted error. This exception was necessary because some
diseases, such as hypertension, are so highly prevalent. Truly
erroneous attempts at ordering antihypertensives would frequently
have to be ruled out as intercepted errors because of the ubiquity
of hypertension diagnoses. To make an assessment in cases where
the patient had a prior, documented indication, reviewers judged
whether the use of the medication was plausible at the time of the
order. For instance, a patient with a history of hypertension who is
admitted for sepsis and hypotension would not be given an order
for a new antihypertensive despite the prior history. A reviewer
could deem this as a non-plausible indication at the time of the
order.
We also excluded cases if the reviewers determined the
medication order was part of medication reconciliation. This
was necessary since the medication reconciliation lists in the EMR
listed medications alphabetically, so the fact that metronidazole
was selected after metformin was cancelled could simply be
because it was the next medication to reconcile, and it might not
represent any drug name confusion.
In the inpatient setting, medications can only be ordered in our
EMR by their generic name. In outpatient and ED areas,
medications could be ordered by either brand or generic names.
For the retrospectively reviewed, canceled orders, we could not
retrieve whether the medication was ordered generic or branded.
In order to better determine the likely name of the ordered
medications in the ambulatory settings, we reviewed prescription
data at the time of the suspected error to look into the relative use
of generic versus brand names. If prescriptions were written 90%
or more of the time as either generic or branded, then we
evaluated that medication solely by the medication name that was
Alerts Intercept Drug Name Confusion Errors
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during chart review were prescribed consistently as either branded
or generic greater than 90% of the time.
Statistical Analysis Plan
We computed the rate of intercepted errors as the number of
intercepted errors divided by the total number of alerts. We used
multivariable logistic regression to examine the effect of potential
covariates on the dependent variable, the probability of an
intercepted error. We considered prescriber type (resident,
attending, other), patient location (inpatient, emergency depart-
ment, outpatient, other), and work shift (7AM-5PM,5 PM-midnight,
midnight-7AM). Because errors with fluticasone/fluticasone nasal
dominated the results, the analysis was done with both the full
cohort and then again excluding fluticasone/fluticasone nasal
cases. The threshold for statistical significance was alpha=0.05.
Figure 1. Example Indication Alert for Levothyroxine.
doi:10.1371/journal.pone.0101977.g001
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University of Illinois Hospital and Health Sciences System (UI-
Health). We obtained a waiver of informed consent for both the
patient and clinician participants.
Results
We analyzed a total of 127,458 indication alerts. The inpatient
setting accounted for 46% of the orders, followed by 35% in the
ambulatory setting, 16% from the ED and 3% other. Resident
physicians accounted for 72% of the orders, attending physicians
21%, nurses 6%, and 1% other. In 2,410 (1.9%) instances the
order was never completed (i.e., ‘‘abandoned’’). Of these 2,410
abandoned orders, 731 met criteria (a), (b) and (c) in our definition
of an intercepted error and were reviewed by clinicians. Chart
review by two independent clinicians identified 176 instances in
which the alert led to the order of a different, similar-sounding
drug, by the same clinician, in the same patient, within five
minutes, with no plausible indication for the initially ordered drug.
This represented an error interception rate of 0.1460.01% (176
intercepted errors out of 127,458 alerts), or 1.4 intercepted errors
per 1000 alerted orders. The 176 errors were comprised of 39
unique pairs of drug names (Table 2). Ranked by overall number
of errors, the most commonly intercepted pairs were fluticasone/
fluticasone nasal, 100 (57%), metoprolol/metoclopramide, 16
(9%), hydralazine/diphenhydramine, 6 (3%), and nitroprusside/
nitroglycerin, 6 (3%).
Of the 39 unique pairs, the similarity between the confused
meds was most commonly having the first 3 letters being identical,
20/39 (51%). Having neither the first or last 3 letters in common
occurred in 10/39 (26%), while having the last 3 letters in
common occurred in 9/39 (23%) of the pairs.
The rate of error interception varied by medication. For many
drugs, like simvastatin, the rate was so low that it could not be
measured with precision different than zero. Nitroprusside, not a
commonly used medication, had a very high interception rate of
roughly one intercepted error per 3 alerted orders. Two
commonly used drugs with relatively high intercepted error rates
were hydralazine (0.2560.07%) and metoprolol (0.1860.04%).
The distribution of intercepted errors as a function of initially
ordered medication shown in Table 2 is dominated by fluticasone.
These intercepted errors were an attempt to prescribe fluticasone
nasal, which is most frequently an outpatient medication. To
understand the relationship between the covariates and the
outcome with and without the influence of the fluticasone cases,
logistic regression was repeated, once including fluticasone cases
and once without. The results are shown in Table 3. Comparison
of the results with and without fluticasone demonstrates the effect
of this one medication on the results.
In both analyses, the likelihood of an intercepted error was
numerically highest with resident physicians. This was a statisti-
cally reliable result in the complete data set and a non-significant
trend when fluticasone was excluded. The ED had a significantly
lower rate of intercepted errors both with and without fluticasone
included in the analysis. The time of day as defined by the shift
was only significantly related to the error interception rate when
fluticasone was excluded, with the evening shift being associated
with roughly half the rate of the day shift.
Discussion
Drug name confusions are a relatively common and persistent
source of medication errors. Even when the confusing pairs of
names are well known, as they often are (e.g., hydroxyzine/
hydralazine), errors have stubbornly resisted eradication. Safety
experts suggest a variety of techniques for minimizing the risk:
storing products with similar names in different locations,
eliminating one of the two confusing products from the formulary,
adding labels to shelves where products are stored, adding
warnings to computer order entry systems, using mixed-case (‘‘tall
man’’) lettering, altering labels and packages among other
interventions
8 In spite of the widespread use of some of these
risk-reduction strategies, especially mixed-case lettering, only
barcoding is strongly evidence-based [6]. One strategy that has
not been widely discussed previously is to incorporate information
from a patient’s problem list and known drug indications into real-
time decision support at the time orders are entered. We
demonstrated here that indication alerts can intercept drug name
confusion errors at a rate of just over one per thousand alerted
orders. This is roughly the same rate at which wrong drug errors,
of which name confusion errors are a subset, have been observed
in inpatient and outpatient studies, though we hasten to add that
the rate we report is only the rate of intercepted errors for a subset
of drugs that had indication alerts turned on [4,7].
Of the 39 unique pairs of names we identified in intercepted
errors, all but 3 (Actonel/Actos, metformin/metronidazole,
hydrozyzine/hydralazine) do not appear on the most widely
circulated list of confusing drug names, suggesting that many more
pairs of names are confused in practice than have been reported in
published sources [21]. About half of the pairs had at least 3-letter
similarity at the beginning of the names, while the others were split
between 3 letter similarities as the end of the names and no 3 letter
similarity at the beginning or end. The half of the pairs that had
similarity at the beginning of the words accounted for 81% of the
drug name confusions. Several error mechanisms may have been
in play, including pick list errors, auto-fill errors and adjacency
errors found either on main selection screens, drop down menus,
order sets, or favorites lists.
We are in the process of analyzing our own order entry screens,
using the identified errors as queries, to see if we can further isolate
system vulnerabilities that increase risk of confusion. For the errors
with dissimilar beginning of names, the error mechanisms are less
clear, but are also likely to involve some combination of visual
perception, auditory perception, short-term memory and motor
control errors [22]. The fact that the error interception rate varied
Table 1. Medications used as Indication Alert Triggers.
Albuterol, aliskiren, alpha blockers, amiloride, angiotensin converting enzyme inhibiters, angiotensin receptor blockers, aspirin-dipyridamole, beta blockers,
bisphosphonates, calcium channel blockers, clonidine, cholestyramine, coagulation factor VIIa, ezetimibe, fibric acids, intravenous immune globulin, fluticasone,
fluticasone/salmeterol, furosemide, glimepiride, guanfacine, HMG-CoA reductase inhibitors, hydralazine, insulins, isosorbide dinitrate, levothyroxine, liotrix, metformin,
methyldopa, metolazone, minoxidil, nateglinide, niacin, nitroprusside, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors,
nucleotide analog reverse-transcriptase inhibitors, nucleotide reverse transcriptase inhibitors, pioglitazone, protease inhibitors, proton pump inhibitors, red yeast rice,
repaglinide, rosiglitazone, selective serotonin reuptake inhibitors, spironolactone, sulfonylureas, thiazides, thyroid desiccated, tiotropium, triamterene
doi:10.1371/journal.pone.0101977.t001
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understand the ramifications for order entry design.
The interception rate is a measure of the potential benefit of the
intervention; however, changes in the interception rate do not
necessarily reflect a change in the underlying error rate because of
the unknown rate of non-intercepted errors. Prescribers must pay
attention at the time of the alert if they are to recognize and
correct errors. A clinician who is hurried and distracted when
ordering may be more likely to produce a drug name confusion
error, but may also be less likely to recognize the error even after
the alert draws attention to the medication name, indication and
patient name. If prescribers do not attend to alerts, the
interception rate may be low despite a high rate of actual errors
because many errors are not being intercepted. As such, the odds
ratios reported in Table 3 are not meant to imply anything more
than the performance of the intervention in intercepting errors.
The data suggest that the intervention was able to intercept more
errors for resident physicians as well as in the inpatient or
Table 2. Distribution of Drug Pairs in Intercepted Errors.
Canceled Order Completed Order No. Errors No. Alerts Error Rate (%)
a Std. Err. (%)
fluticasone fluticasone-nasal 100 4565 2.19 0.22
metoprolol metoclopramide 16 9936 0.16 0.04
nitroprusside nitroglycerin 6 19 31.6 10.7
hydralazine diphenhydramine 6 4346 0.14 0.06
propranolol propofol 5 2931 0.17 0.08
nimodipine famotidine 3 511 0.59 0.34
clonidine famotidine 3 2350 0.13 0.07
metformin metronidazole 3 6148 0.05 0.03
fluticasone-salmeterol fluticasone-nasal 2 3166 0.06 0.04
hydralazine hydromorphone 2 4346 0.05 0.03
hydralazine hydroxyzine 2 4346 0.05 0.03
methyclothiazide methylergonovine 1 1 100 0.00
minoxidil minoxidil-topical 1 48 2.08 2.06
tenofovir atenolol 1 101 0.99 0.99
metolazone metoclopramide 1 132 0.76 0.75
ibandronate ibuprofen 1 133 0.75 0.75
methyldopa methylprednisolone 1 138 0.73 0.72
Actonel
b Actos 1 150 0.67 0.66
felodipine Feldene 1 177 0.57 0.56
nimodipine morphine 1 511 0.20 0.20
paroxetine pyridoxine 1 1071 0.09 0.09
tiotropium tenofovir 1 1581 0.06 0.06
nifedipine prednisone 1 2111 0.05 0.05
clonidine ranitidine 1 2350 0.04 0.04
lansoprazole alprazolam 1 2381 0.04 0.04
propranolol lansoprazole 1 2931 0.03 0.03
amlodipine amitriptyline 1 3183 0.03 0.03
amlodipine famotidine 1 3183 0.03 0.03
atorvastatin multivitamin 1 3204 0.03 0.03
hydralazine chlorzoxazone 1 4346 0.02 0.02
sertraline tetracycline 1 4529 0.02 0.02
levothyroxine levofloxacin 1 5642 0.02 0.02
hydrochlorothiazide hydrocortisone 1 6040 0.02 0.02
hydrochlorothiazide hydroxyzine 1 6040 0.02 0.02
metformin metoprolol 1 6148 0.02 0.02
metformin multivitamin 1 6148 0.02 0.02
metoprolol ketorolac 1 9936 0.01% 0.01%
metoprolol metronidazole 1 9936 0.01% 0.01%
simvastatin simethicone 1 13625 0.01% 0.01%
aThe interception rate is the number of errors (confirmed by clinician chart review) divided by the total number of alerts for that drug.
bIn this pair, at the time of the alert, the branded names were most common, .90%.
doi:10.1371/journal.pone.0101977.t002
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the actual error rate differed across these settings. The actual error
rate remains unknown.
In addition to the interception rate, the value of the alerts
should also be assessed by considering the severity of the potential
harm prevented by intercepting certain errors. Although we did
not conduct a formal assessment of the clinical severity of the
intercepted errors, several, by their very nature, have the potential
for significant harm. Examples include high-alert medications like
metoprolol, propofol, morphine and others.
The results of this study, together with prior work by our group,
suggest that indication alerts can have 3 beneficial effects:
improvement of the problem list, [13] interception of wrong
patient errors,
16 and interception of drug name confusion errors.
None of these benefits was found in a system operating across all
medications, and, in the case of problem list additions, indication
alerts for some medications are known to perform poorly [15]. In a
recent analysis of all alerts for antihypertensive medications, the
accuracy and yield of problem list additions varied greatly and
was, at least in part, related to the number of potential indications
associated with the medication being ordered [14].
To the prescribing clinician, the alert’s function is to help with
problem list placement. Error interception is rare and does not add
any nuisance to the alerts. Documented variability in the
effectiveness of indication-based alerts demonstrates that they
must be designed thoughtfully. To minimize nuisance, great care
must be given to selecting medications with a limited number of
well-documented indications and to incorporating an exhaustive
list of exclusion diagnoses so that alerts will not trigger when the
patient has a legitimate indication.
Limitations
We conducted the study in a hospital that has been using CPOE
for more than 20 years and in a teaching environment where
prescribers are accustomed to alerts. Many settings lack CPOE,
EMR and electronic CDS, and virtually none prompt physicians
with alerts about missing problems that are linked to drug orders,
although the capability to perform CPOE with this type of
decision support is becoming more widespread. As a result, the
performance we observed may not be generalizable to settings
unlike the one we studied. We used established measures (e.g.,
Editex and BiSim) to measure similarity between the initial name
and the subsequently ordered name, but the threshold value we
used to define what counted as a name confusion (as opposed to
any other type of wrong drug error) was chosen empirically, based
on an examination of the distribution of similarity scores for a
large set of name pairs. Using a different threshold would impact
the number of order changes we defined as drug name confusions.
We did not interview the prescribers who intercepted their own
errors, nor did we directly observe them during order entry, so our
understanding of the precise mechanism by which the alerts
functioned is incomplete. Finally, this analysis likely underestimat-
ed the true frequency of wrong drug orders since we suspect many
alerts were ignored or suppressed by the computer when a
plausible problem was on the problem list.
Conclusions
Indication alerts have been shown to improve problem list
documentation and to intercept wrong patient medication errors.
In this study we demonstrated that indication alerts intercepted 1.4
drug name confusion errors per 1000 alerted orders. Institutions
with CPOE should consider implementing indication prompts
both to improve the quality of problem lists and to prevent drug
name confusion errors and wrong patient errors. Further
enhancements to maximize the benefit of this novel form of
CDS while minimizing nuisance, likely through careful design and
selection of medications, indications, prescribers, and locations, is
necessary.
Table 3. Association between Clinician Type, Location, Shift and Probability of an Intercepted Drug Name Confusion Error.
Variable
a With Fluticasone Without Fluticasone
Odds Ratio Confidence Interval Odds Ratio Confidence Interval
Clinician Type
Resident - - - -
Attending 0.35
b 0.23–0.54 0.69 0.30–1.56
Nurse 0.53
c 0.28–0.996 0.69 0.21–2.26
Location
Inpatient - - - -
Ambulatory 3.54
b 2.51–5.00 0.51
c 0.27–0.95
ED 0.27
c 0.11–0.68 0.29
c 0.11–0.72
OR 0.27 0.04–1.98 0.29 0.04–2.09
Shift
Day - - - -
Evening 0.80 0.55–1.16 0.47
c 0.23–.95
Overnight 0.74 0.44–1.27 1.05 0.52–2.12
aResident physician, inpatient location and day shift were used as reference categories. Testing global null hypothesis for model with fluticasone, 22 log likelihood
=2563.8, chi-square =94.9, p,.0001. For model without fluticasone, 22 log likelihood =1245.9, chi-square =24.6, p,.0001.
bp,0.001.
cp,0.05.
doi:10.1371/journal.pone.0101977.t003
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